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Background: Due to increasing the complexity of breast cancer treatment it is of paramount importance to
develop structured care in order to avoid a chaotic and non-consistent management of patients. Clinical pathways,
a result of the adaptation of the documents used in industrial quality management namely the Standard Operating
Procedures, can be used to improve efficiency and quality of care. They also aim to re-centre the focus on the
patient’s overall journey, rather than the contribution of each specialty or caring function independently.
Methods: The effect of the implementation and prospective systematic evaluation of a clinical care pathway for the
management of patients with early breast cancer in a single breast unit is evaluated over a long time interval (between
2002 and 2010). Annual analysis of predefined clinical outcome measures, service indicators, team indicators, process
indicators and financial indicators was performed. Pathway quality control meetings were organized at least once a
year. Systematic feedback was given to the team members, and if necessary the pathway was adapted according to
evidence based literature data and in house pathway related data in order to improve quality.
Results: The annual number of patients included in the pathway (289 vs. 390, P <0.01), proportion of patients with
Tis-T1 tumors (42% vs. 58%, P <0.01), negative lymph nodes (44% vs. 58%, P <0.01) and no metastases at diagnosis
(91.5% vs. 95.9%) has risen significantly between 2002 and 2010. Evolution of mandatory quality indicators defined by
EUSOMA shows a significant improvement of quality of cancer care. Particularly, the proportion of patients having
anti-hormonal therapy (84.8% vs. 97.4%, P = 0.002) and adjuvant chemotherapy according to the guidelines (72% vs.
95.6%, P = 0.028) increased dramatically. Patient satisfaction improved significantly (P <0.05). Progression free 4-year
survival was significantly higher for all patients, for T1 tumors only and for T2-T4 tumors only, treated between 2006 to
2008 compared to between 1999 to 2002 and 2003 to 2005 (P = 0.006, P = 0.05, P = 0.06, respectively). Overall 4-year
survival of the entire population treated between 2006 and 2008 was significantly better (P = 0.05).
Conclusions: Although the patient characteristics changed over the years due to better screening, this clinical
pathway and regular audit of quality indicators for the treatment of patients with operable breast cancer proved to be
important tools to improve the quality of care, patient satisfaction and outcome.
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Several publications have suggested that the quality of
health care received by patients in the Western world does
not always match the ideal care. In a survey of 30 health
conditions ranging from osteoarthritis to breast cancer,
McGlynn et al. observed that on average Americans
received about half (54.9%) of the recommended medical
care processes [1]. It has also been reported that in Europe
there are wide differences in treatment offered to patients
with breast cancer in terms of mastectomy and radiother-
apy rates and the use of adjuvant chemotherapy and
hormone therapy, which results in considerable survival
differences [2,3]. These observations highlight a gap
between optimal and actual care, that is, between
what evidence has identified as recommended care
and what patients actually receive [4]. They show that
there is a worldwide need for tools to improve adherence
to guidelines in the daily clinical practice.
High-quality services are essential to optimize treat-
ment results of women with breast cancer. They can be
achieved by accurate training, specialization, volume
levels and a multidisciplinary approach, involving many
different subspecialists, nursing staff and supporting
staff members [5]. Due to the increasing complexity
of breast cancer treatment and the teams involved, it
is of paramount importance to develop structured
care in order to avoid a chaotic and non-consistent
management of patients.
A clinical care pathway is a methodology for the
mutual decision making and organization of care for a
well-defined group of patients during a well-defined
period of time [6]. The aim of a clinical care pathway is to
improve quality of care, reduce risks of unintended effects
and death, increase patient satisfaction and improve
efficiency of resource usage [7]. Clinical care pathways
are developed by multi-professional teams, composed by
different types of physicians, nurses, social workers and
administrators, who manage disease processes and are
responsible for patient care [8]. Continuous evaluation
and follow-up of quality indicators should guarantee the
effectiveness of a clinical care pathway. Five domains for
evaluation can be distinguished: clinical outcome, ser-
vice indicators, team indicators, process indicators and
financial indicators [9]. A review on quality of cancer
care, guidelines and clinical pathways demonstrated
improvements in compliance to guidelines and evi-
dence based medicine, and reduction of length of
hospital stay, complication rates and financial costs
[10]. The present paper describes the effects of the
development, implementation and prospective system-
atic evaluation and adaptation of a clinical care path-
way for the management of patients with operable
breast cancer in a single breast unit over a long time
interval (between 2002 and 2010).Methods
The hospital setting
The Sint-Augustinus Hospital is a non-academic teaching
hospital in Belgium. The Oncology Unit of the hospital is
integrated in a local cancer network (Iridium Network),
collaborates closely with Leuven University, Belgium, and
is the second largest of Flanders. Every year up to 400 new
breast cancer patients receive surgical treatment in this
unit. Most patients are referred by local GP’s or the
regional screening units.
Given that the multidisciplinary oncology team consisted
of more than 40 physicians of different specialties,
50 members of the nursing staff, and 10 social workers
and psychologists, a clinical pathway for the diagnosis,
surgical treatment and decision making of adjuvant
treatment in patients with operable breast cancer was
developed in 2002 in an attempt to provide more uniform
cancer care. Patients with a suspicious breast lesion obtain
an appointment in the oncology outpatient clinic within
two days, and by triple assessment a rapid diagnosis is
achieved within five days. The postoperative multidiscip-
linary breast team meeting (held twice a week) outlines an
individualized postoperative treatment plan based on the
local cancer network guidelines (adaptation of the Sankt
Gallen guidelines) [11-15]. Further treatment is carried
out according to this plan if the patient agrees. Multidis-
ciplinary follow-up is organized every 3 months, the first 3
years and biannually on the fourth and fifth year.
In 2005 a breast nurse was introduced to facilitate the
patient’s journey through the multidisciplinary track and
to be a gate-keeper of the clinical pathway. From January
2006 onwards immunohistochemical assessment of estro-
gen receptor, progesterone receptor and c-erbB-2 was stan-
dardized using FDA approved FARM DX and Herceptest
Dako immunohistochemistry (Dako, Carpinteria, CA,
USA) [16,17]. In January 2007 the Breast Clinic of the
Sint-Augustinus Hospital was formally opened. It was
organized according to European Society of Breast Cancer
Specialists (EUSOMA) guidelines [18]. A breast multidis-
ciplinary core team consisting of full-time breast surgeons,
medical oncologists, radiotherapists, breast radiologists,
histopathologists, breast care nurses, database manager,
clinical geneticist, psychologists and reconstructive
surgeons, was established. All patients with a new breast
cancer diagnosis have a preoperative visit with a member
of the core team. In addition a preoperative multidiscip-
linary meeting was introduced. Adaptations to the clinical
pathway were made in 2008 in order to make it com-
patible with Flemish requirements for breast clinics. In
2008 the breast clinic of the Sint-Augustinus Hos-
pital obtained its formal accreditation by the Flemish
Government and EUSOMA [19]. Two new breast nurses
were incorporated in the team in 2009, as our original
breast nurse moved up in the administrative staff of the
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receive a European Cancer Care Certificate, a quality label
for breast cancer care. The pathology laboratory received
an ISO2000 accreditation in 2010.
Prospective data collection
As the hospital management wishes to guarantee high
quality care by improving processes, since 2002, perform-
ance measurements have been documented systematically
by care providers using an order communication, planning
and result reporting system [20]. The nursing process is
integrated in the clinical pathway “operable breast cancer”.
The order communication system “patient care system”
(PCS) is an IBM (New York, USA) mainframe based
application working under Customer Information Control
System (CICS) and using a Data Language One (DL/I)
database. It has been completely adapted to the hospital
requirements, by its own IT staff. It is developed as a level
three electronic patient record as described by Brennan
[21]. It contains clinical ward based applications including
order communications and results reporting, multidiscip-
linary clinical pathways, electronic prescribing and drug
administration.
The documentation process was improved by setting
up a structured organization of data collection into the
hospital informatics system, based on clear procedures
discussed with care providers to make sure the data
collection was achievable. As input of the many process
parameters was very time consuming, it was decided to
collect data and monitor them for the first half of every
calendar year, so that in the second half of the year other
care pathways could be assessed. Patient satisfaction was
measured prospectively in 60 consecutive patients prior to
discharge at the beginning of every year. A previously vali-
dated questionnaire developed by the Belgian-Dutch Clin-
ical Pathway Network (BDCPN) on 19 different aspects of
organization of care was used. It is based on a larger ques-
tionnaire developed by Chou et al. [22], and adapted and
translated from English to Dutch. Questions were
scored from 1 to 4 (1: dissatisfied; 2: more or less
dissatisfied; 3: more or less satisfied; 4: satisfied). The
responsibility for gathering correct data was identified
and a structured follow-up was organized. Feedback
and discussion of data and information of the respon-
sible team was organized annually.
Clinical pathway
The clinical pathway “operable breast cancer” was
developed by the methodology described by the BDCPN
[23]. The multidisciplinary team formulated the outcome
parameters, critical indicators and key activities to deal
with the patient’s condition. The clinical pathway is de-
scribed by a time task matrix and integrated into the IT
system PCS. The latest version of our clinical pathwayoperable breast cancer is attached to this manuscript
(Additional file 1). Annual analysis of predefined clinical
outcome measures, service indicators, team indicators,
process indicators and financial indicators was performed.
Pathway quality control meetings were organized at least
once a year with the members of the core team, other
medical providers and the hospital administrators.
Systematic feedback was given to the team members,
and if necessary the pathway was adapted according to
evidence based literature data and in-house pathway
related data in order to improve quality. Survival data
were collected systematically for patients included in the
in-house electronic patient records. If the patients were not
followed in our hospital, their general practitioners were
annually contacted to provide survival related information.
Statistical analysis
The SPSS6 package was used for the statistical analysis
of the data.
Results
Characteristics of the patients treated between 2002 and
2010 are given in Table 1. As can be seen the number of
patients included in the pathway and proportion of
patients with small tumors, negative lymph nodes and no
metastases at diagnosis has risen significantly over the
years. Histological subtypes have remained the same, but
the proportion of patients with hormone receptor negative
tumors dropped significantly after the introduction of
PharmDX immunohistochemical determination of hor-
mone receptors in 2006.
Table 2 shows the major clinical indicators between
2002 and 2010, indicating that the average length of
hospital stay nearly halved and the proportion of breast
conserving surgery, preoperative guide-wire localization
for impalpable lesions and use of sentinel node biopsy
increased significantly. Median duration of hospital stay
was reduced for patients treated by mastectomy or breast
conserving surgery from 9 and 4 days in 2002 to 7 and 2.5
days in 2010, respectively (P <0.01). The percentage of
second surgery (to achieve free margins by additional local
resection or mastectomy, or to perform a complete
axillary dissection after a sentinel node biopsy which
was negative during preoperative assessment but proved
to contain metastatic cells at final pathological analysis)
dropped from 25 to 10% (P <0.01). Sentinel node biopsy
was introduced between 2005 and 2006, and its use
remained stable over the years. Staging examinations have
increasingly been performed preoperatively over the years.
In 2009, when we had to incorporate two new breast
nurses, a temporary drop of incompletely met discharge
criteria was noted, which was corrected in 2010 after these
nurses were further trained. “Completeness of dis-
charge criteria” and “normal wound at discharge” were
Table 1 Patient characteristics between 2002 and 2010 in the clinical pathway “operable breast cancer”
Indicator 2002 2003 2004 2005 2006 2007 2008 2009 2010
Number of patients in pathway 140 130 130 108 164 176 146 169 183*
Percentage pTis-pT1 (%) 42 39 60 55 55 58 60 55 58*
Percentage pN0 (%) 44 52 46 48 51 58 57 52 58*
Percentage M1 at diagnosis 8.5 8.4 5.7 10 4.5 7.7 5.5 2.6 4.1*
Percentage IDC (%) 78 76 84 84 77 79 81 79 81*
Percentage ER negative (%) 26 21 34 31 19 20 23 18 18*
*: P <0.05 comparing 2002 vs. 2010.
IDC: invasive ductal carcinoma, ER: estrogen receptor.
Data were collected in the first semester of each year.
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evaluation period compared to the first half (2003 to
2005).
Table 3 shows clinical indicators on postoperative day
1 which remain stable over the years. Of the EUSOMA
indicators, ten are currently being monitored for the
purpose of Cancer Care Certification by the use of the
EUSOMA multi-institutional European Database. The
time trend in results of these ten indicators in our unit
is shown in Table 4. It can be seen that most of these
indicators were significantly better in 2010 compared to
2003. EUSOMA criteria were met for all indicators in
2010. In Table 5 patient satisfaction is outlined. This clearly
shows that patient satisfaction improved progressively over
the years and was maximal in early 2009. There was a
significantly higher patient satisfaction for 13 out of 19
parameters (P <0.05) measured in 2009 compared to
2003. The general level of patient satisfaction was very
high. A slight drop in patient satisfaction was noted when
the breast nurses changed at the end of 2009. Special
teaching sessions were organized to improve this, and
were clearly effective (Table 5). Progression free 4-year
survival was significantly higher for all patients, for T1 tu-
mors only and for T2-T4 tumors only, treated between
2006 and 2008 compared to between 1999 and 2002 andTable 2 Process indicators in the period 2002 to 2010 in the
Indicator 2002 2003
Number of patients in pathway 140 130
Total days of hospital stay (d) 991 913
Average hospital stay/patient (d) 7.0 7.0
Breast conserving surgery (N, %) 60(43) 58(45)
Preoperative guide wire (N, %) 20(14) 26(20)
Sentinel node biopsy (N, %) 0(0) 7(5)
Preop staging tests (N, %) 74(53) 61(47)
All discharge criteria not Satisfactory (N, %) NR 16(12)
Wound not satisfactory at Planned discharge (N, %) NR 4(3)
N: number of patients, d: days; %: percentage; NR: not recorded.
*: P <0.05 comparing 2002 vs. 2010.
Data were collected in the first semester of each year.2003 and 2005 (P = 0.006, P = 0.05, P = 0.06, respect-
ively) (Figure 1). Overall 4-year survival of the entire
population treated between 2006 and 2008 was signifi-
cantly better (P = 0.05).Discussion
The clinical pathway concept appeared for the first time
at the New England Medical Center (Boston, USA) in
1985 inspired by Zander and Bower [7]. Clinical pathways
were a result of the adaptation of the documents used in
industrial quality management, the Standard Operating
Procedures, whose goals are to improve efficiency in the
use of resources and to finish work in a set time. They also
aim to re-centre the focus on the patient’s overall journey,
rather than the contribution of each specialty or caring
function independently. The difference between a pathway
and a guideline is that a guideline defines the numerous
acceptable treatment options that fall within the standard
of care, whereas a pathway drives physicians toward a
single treatment with predictable toxicities and minimal
cost. Although the majority of patients are treated
according to the pathway, it is possible for the team not to
comply with the pathway for a particular case, but the
reasons to do this have to be clearly documented.clinical pathway “operable breast cancer”
2004 2005 2006 2007 2008 2009 2010
130 108 164 176 146 169 183 *
980 651 936 872 730 848 745
7.5 6.0 5.7 4.9 5.0 5.0 4.1*
58(45) 56(52) 86(53) 104(59) 82(56) 96(57) 106(58)*
27(21) 23(21) 36(22) 28(16) 28(20) 35(21) 50(27)*
29(22) 48(44) 74(45) 82(46) 58(39) 64(38) 90(49)*
56(43) 16(15) 38(23) 46(26) 19(13) 70(30) 22(12)*
19(15) 16(15) 18(11) 14(8) 7(5) 30(18) 16(9)
12(9) 10(9) 3(2) 3(2) 0(0) 5(3) 6(3)
Table 3 Clinical indicators on the first postoperative day in the period 2004 to 2010 in the clinical pathway “operable
breast cancer”
Indicator 2004 2007 2008 2009 2010 P value (2004–2010)
Drainage first 24 hours (mL) 28.6 25.0 26.4 27.9 25.1 NS
VAS score >3 (N) 38(29) 19(10) 19 65 49 NS
Postoperative vomiting first 24 hours (N) 2(2) 2 3 9 11 NS
Postoperative fever (37.9°C) (N) 0(0) 1 3 0 0 NS
Norton score (average day 1) 20.0 19.9 19.9 19.8 19.9 NS
NS: not significant, N: number of patients.
Data were collected in the first semester of each year.
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breast cancer care are limited to a few small studies.
Kasahara and Tawaraya, in Japan, used five clinical
pathways for the treatment of breast cancer patients
[24]. They concluded that the clinical pathway brought
standardization in their institution. The clinical pathway
proved to be useful in coping with alternative operating
methods, increased the use of adjuvant chemotherapy and
increased the number of patients treated as outpatients.
Santoso et al. showed, in a prospective analysis of aTable 4 Evolution of quality indicators as formulated by EUSO




Positive preoperative cyto/histological diagnosis
80% 9
Operated invasive carcinoma for which hist. type, grading ER/PR, stage and s
90% 9
Operated non invasive carcinoma for which size, histological type and gradin
95% 9
More than 9 lymph nodes removed when ALD performed (excluding sampli
95% 9
Postoperative radiotherapy in M0 invasive CA with BCT
90% 9
BCT in invasive carcinoma with total size up to 30 mm (including DCIS comp
70% 8
BCT in carcinoma in situ up to 20 mm
70% 8
Ductal carcinoma in situ without axillary dissection
80% 9
Hormonotherapy in endocrine sensitive invasive carcinoma
80% 9
Adjuvant chemotherapy in ER- (PT1c+ or N+) invasive Carcinoma
80% 9
N: number of patients; %: percentage of successful outcome measure/total number
node dissection; BCT: breast conserving therapy; DCIS: ductal carcinoma in situ; signmastectomy clinical pathway over a seven month period
in Singapore, that implementation of the clinical pathway
improved consistency in patient treatment, the quality of
patient outcome, and reduced costs of care and length of
stay [25]. Hwang et al. found, in a retrospective analysis of
29 patients undergoing a transverse rectus abdominis
breast reconstruction included in a clinical pathway
compared to 40 similar non-pathway patients, that im-
plementation of the reconstruction clinical pathway
resulted in significant declines in length of stay andMA prospectively evaluated between 2003 and 2010
2003 2010 P value
arget N % N %
77/130 59.7% 161/183 88.4% 0.0001
0%
ize were recorded 106/112 94.6% 178/181 98.3% 0.1467
5%
g are recorded 5/7 71% 28/29 96.5% 0.4966
8%
ng) 97/112 85.6% 67/70 95.7% 0.0434
8%
50/51 98% 105/108 97.2% 0.7588
5%
onent) 49/79 62% 86/104 82.6% 0.0016
0%
3/7 43.8% 11/14 78.6 0.0016
0%
6/7 85.7% 22/23 95.6% 0.3560
0%
89/105 84.8% 151/155 97.4% 0.0002
0%
18/25 72% 22/23 95.6% 0.0280
0%
of cases; ER: estrogen receptor; PR: progesterone receptor; ALD: axillary lymph
ificance level calculated with two-tailed χ2 test without Yates correction.
Table 5 Patient satisfaction in the clinical pathway “operable breast cancer” (systematically scored prospectively on 60
consecutive patients in the beginning of the year between 2003 and 2010)
Satisfaction indicator Year
How satisfied were you about: Significance level (P value)
2003 2004 2005 2006 2008 2009 2010 2003-2009 2009-2010
Information on how to prepare your stay in the hospital
79 72 77 98 98 100 85 0.001 0.01
Information on the course of your stay (moment of admission until discharge)
85 85 87 93 97 98 92 0.05 NS
Information on how to prepare for a test or a treatment
85 87 90 98 98 100 96 0.01 NS
Explanation of the provided care before and during it was carried out
91 92 90 95 98 100 93 NS NS
Information on your disease
87 90 98 98 97 98 98 NS NS
Information which you received concerning the possible assistance after your discharge
77 90 97 95 98 95 98 0.007 NS
Uniformity of information you received from care providers
75 87 93 95 90 100 97 >0.001 NS
Smooth completion of your admission to the hospital
92 95 96 98 98 95 95 NS NS
Consecution of investigative tests, interventions and general organization of care
92 92 93 98 100 100 92 0.05 NS
Waiting times during your hospital stay
75 100 97 85 90 97 82 0.002 NS
Complying of doctors and nurses with appointment during your stay
90 90 93 93 95 100 88 0.03 0.03
Hospital staff caring about a person, in a sense that you were not just a part of their job
70 95 97 97 100 100 98 >0.001 NS
Preparation you received to care for yourself after the moment of discharge
80 90 97 100 92 100 97 >0.001 NS
Degree in which you felt ready to leave the hospital at the moment of discharge
90 95 97 97 100 100 97 0.03 NS
Kindness of the care providers
90 97 100 100 100 98 98 NS NS
Similarity of implementation of returning care
88 90 95 97 98 98 100 NS NS
Teamwork among doctors, nurses, physiotherapists and other hospital staff
95 97 98 100 98 100 100 NS NS
Guarantees of your privacy and dignity during your stay
90 92 97 97 100 100 100 0.03 NS
Initiative to keep your family well informed on your conditions
66 92 92 98 100 100 100 >0.001 NS
Significance level calculated by χ2 test; Figures are given as percentages of patients satisfied or very satisfied.
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Figure 1 Progression free and overall survival respectively of the entire population: (A) and (B); patients with T1 tumors only: (C) and
(D); and patients with T2-T4 tumors only: (E) and (F). Blue lines: patients treated in 1999-2002, green line: patients treated in 2003-2005,
purple line: patients treated in 2006-2008.
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[26]. Lee et al. showed that a clinical pathway for deep in-
ferior epigastric perforans flap breast reconstruction re-
duced operating time and costs, and improved quality
measures and staff satisfaction [27]. Ryhanen et al. dem-
onstrated that clinical pathways can be used to increase
patients’ knowledge of their disease and empowerment
[28].
Goebel et al. concluded that clinical pathways can pre-
vent malpractice lawsuits in breast cancer and radiation
therapy [29]. In their retrospective analysis from the
LexisNexis and Westlaw legal databases, they found that if
physicians had adhered to clinical pathways, 49 out of 72
law-suits decided in favor of the plaintiff patient could have
been avoided. In a recent project in Michigan it was sug-
gested that the use of a breast cancer pathway reduces er-
rors and costs, and increases efficiency [30]. These authors
also found that patient satisfaction had increased since
pathways were implemented. Particularly in an era of per-
sonalized medicine, clinical pathways are a tool to establisha model of care that drives oncologists towards evidence
based medicine with measurable outcomes in order to
achieve high quality patient outcomes at an affordable cost.
The present paper is the first to describe a prospective
long-term analysis of the use of a clinical pathway to
optimize management of large cohorts of patients with
operable breast cancer. It clearly shows that a pathway
can be a useful tool to assure uniform care and to improve
adherence to guidelines. Continuous registration of quality
indicators, treatment related data and regular feedback of
the outcomes to the breast team improved quality of care
significantly. Evaluation of the pathway data allows for
corrective measures to improve care. When, for example,
we noted more postoperative pain on day two in 2008 or
more vomiting in 2010, a meeting was organized with the
anesthetists, in order to improve the pathway. These
corrective measures were effective and reduced these
symptoms adequately. It should be mentioned that the
exact “cocktail” of medication used for general anesthesia
is not part of the pathway and depends on the preference
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tion was noted in 2009 when our original breast nurse
moved up in the organization and was replaced by two full
time breast nurses due to the increased workload. Particu-
larly information for patients on how to prepare for their
stay in the hospital, the waiting times during the hospital
stay and compliance of doctors and nurses with appoint-
ments during the patients hospital stay was significantly
lower. Special sessions were held with the breast nurses
individually and with the entire core team, to bring this
back to normal.
A recent Taiwanese study shows that when breast
cancer patients are diagnosed and treated in complete
accordance with widely accepted standards of care, they
survive longer and have better outcomes [31]. This
prospective study followed 1,378 newly diagnosed
breast cancer patients from 1995 to 2001 in a single
cancer hospital, tracking 10 indicators of care quality
and assessing the progression of disease up to June
2007. Adherence to all 10 quality indicators by patients
was associated with better overall (HR: 0.46; 95% CI:
0.33 to 0.63) and progression-free survival (HR: 0.51;
95% CI: 0.39 to 0.67). Adherence to either the four
treatment indicators, or the six diagnostic indicators by
patients was also associated with a significant improve-
ment of survival. In the present study 4-year progression
free survival was significantly better in the cohort of
patients treated in 2006 to 2008 compared to 2004 to
2005 and 2002 to 2003. Similar results were obtained
after data were stratified for T1 tumors only and T2-T4
tumors. Although our survival results can partly be
explained by an evolution in the case mix, with consid-
erably more patients with small tumors and negative
lymph nodes in more recent years, better adherence to
guidelines is likely to be beneficial for the outcome of
the patients. In 2010 more than 97%, 97% and 95% of
patients had state of the art adjuvant radiotherapeutic,
anti-hormonal or cytostatic treatment, respectively, when
indicated (according to the Sankt Gallen guidelines),
compared to 98%, 85% and 72% in 2003. A benchmarking
system of the quality of breast cancer care by a nationwide
voluntary collaborative network of breast centers in
Germany showed similar results [32]. Monitoring
pre-defined quality indicators significantly improved
preoperative histological confirmation of diagnosis
(58% in 2003) to 88% in 2008, appropriate endocrine
therapy in hormone receptor positive patients (27 to 93%),
appropriate radiotherapy after breast conserving therapy
(20 to 79%) and appropriate radiotherapy after mastectomy
(8 to 65%).
Conclusions
EUSOMA has started a voluntary certification process to
assess the clinical performance in dedicated Europeanunits [5,18,33]. So far, 32 breast units in Europe have
been recognized to comply with the requirements
requested by EUSOMA and other European Union
guidelines on the basis of information collected by a
questionnaire and by a site visit carried out by an in-
dependent team of breast cancer experts. A set of quality
indicators was defined by experts from different disci-
plines based on a literature review. These clearly defined
quality parameters, continuous internal audit and external
social control by means of a site visit are of paramount
importance to optimize adherence to evidence based
guidelines and treatment results. The present data shows
that data collection results in knowledge which can be
used for the benefit of the patients. Clinical pathways for
breast cancer have proven to be useful tools to implement
better breast cancer care.
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